Intuitive Surgical Inc. (Sunnyvale, Calif.) reported strong 3Q15 earnings and is continuing a pattern of growth it has shown over the last few quarters. The company surpassed estimates and reported GAAP net income of $167 million, or $4.40 per diluted share for 3Q15, compared with $124 million, or $3.35 per diluted share, for 3Q14. Revenue rose to $589.7 million from $550 million, also ahead of estimates of $579 million.
It probably wouldn't be too far-fetched to call Silk Road Medical (Sunnyvale, Calif.) a giant awakening from its slumber. The private company was formed back in 2007, but has remained relatively quiet – amassing funding and securing patents on technology that could be used in transcarotid artery revascularization (TCAR) procedures to reduce the risk of strokes. But the company's quiet phase is rapidly drawing to a close. It just reported it has received up to $57 million in equity and debt funding from new and existing investors.
Edwards Lifesciences (Irvine, Calif.) has won FDA approval for a valve-in-valve indication for the Sapien XT. The approval opens up the door for Edwards to address an additional patient population that its rival Medtronic (Dublin) already had access to through its Corevalve Evolut valve.
Competitors Medtronic (Dublin) and C.R. Bard (Murray Hills, N.J.) placed a huge spotlight on drug-coated balloons (DCB) with two studies the companies released this week, during this year's Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
SAN FRANCISCO — Tryton Medical (Durham, N.C.), a private company, reported it has met its primary endpoints from a pivotal confirmatory study surrounding the acceptable acute safety profile of the Tryton Side Branch Stent for the treatment of coronary bifurcation lesions in vessels appropriate for a ≥2.5mm stent. Results of the study were presented as part of the featured here at the clinical research session at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
SAN FRANCISCO — Just a little more than half a year ago, Boston Scientific (Marlborough, Mass.) received one of the most monumental approvals of 2015 when it won the FDA nod for its stroke-fighting Watchman device. In that time, the company has been gathering data; seeking reimbursement; and training physicians on how to use the device. Medical Device Daily spoke with Ken Stein, chief medical officer with the Cardiac Rhythm Management business unit at Boston Scientific from the company's booth, during the Transcatheter Cardiovascular Therapeutics annual meeting, to discuss what's next for the technology.
